UBS O'Connor’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.96M | Sell |
104,890
-5,494
| -5% | -$103K | 0.1% | 147 |
|
|
2025
Q1 | $1.99M | Buy |
110,384
+26,073
| +31% | +$469K | 0.06% | 115 |
|
|
2024
Q4 | $1.42M | Sell |
84,311
-32,604
| -28% | -$548K | 0.04% | 194 |
|
|
2024
Q3 | $1.89M | Buy |
116,915
+24,467
| +26% | +$396K | 0.05% | 180 |
|
|
2024
Q2 | $760K | Buy |
92,448
+25,173
| +37% | +$207K | 0.02% | 324 |
|
|
2024
Q1 | $996K | Sell |
67,275
-22,659
| -25% | -$335K | 0.03% | 272 |
|
|
2023
Q4 | $1.3M | Sell |
89,934
-25,243
| -22% | -$366K | 0.04% | 237 |
|
|
2023
Q3 | $1.24M | Buy |
115,177
+12,500
| +12% | +$135K | 0.02% | 300 |
|
|
2023
Q2 | $1.32M | Buy |
102,677
+26,926
| +36% | +$347K | 0.03% | 350 |
|
|
2023
Q1 | $1,000K | Buy |
+75,751
| New | +$1,000K | 0.02% | 399 |
|
|
2022
Q4 | – | Sell |
-28,614
| Closed | -$338K | – | 252 |
|
|
2022
Q3 | $338K | Sell |
28,614
-14,506
| -34% | -$171K | ﹤0.01% | 800 |
|
|
2022
Q2 | $487K | Buy |
+43,120
| New | +$487K | 0.01% | 799 |
|
|
2018
Q3 | – | Sell |
-45,000
| Closed | -$1.27M | – | 304 |
|
|
2018
Q2 | $1.27M | Buy |
+45,000
| New | +$1.27M | 0.03% | 191 |
|